The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2017 | Eagerly anticipated results of the FLAURA trial
Sanjay Popat, BSc MBBS FRCP PhD, from the Royal Marsden Hospital, London, UK, discusses the The FLAURA study (NCT02296125) at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. The FLAURA study investigated patients with EGFR mutant non-small cell lung cancer. Patients were randomised to either gefitinib or erlotinib, the primary endpoint of the trial being progression free survival. The results of this trial were positive, and vey eagerly awaited.
